US President-elect Joe Biden may have promised a “return to normalcy,” but the truth is that there is no going back. The world is changing in fundamental ways, and the actions the world takes in the next few years will be critical to lay the groundwork for a sustainable, secure, and prosperous future.
For more than 25 years, Project Syndicate has been guided by a simple credo: All people deserve access to a broad range of views by the world’s foremost leaders and thinkers on the issues, events, and forces shaping their lives. At a time of unprecedented uncertainty, that mission is more important than ever – and we remain committed to fulfilling it.
But there is no doubt that we, like so many other media organizations nowadays, are under growing strain. If you are in a position to support us, please subscribe now.
As a subscriber, you will enjoy unlimited access to our On Point suite of long reads and book reviews, Say More contributor interviews, The Year Ahead magazine, the full PS archive, and much more. You will also directly support our mission of delivering the highest-quality commentary on the world's most pressing issues to as wide an audience as possible.
By helping us to build a truly open world of ideas, every PS subscriber makes a real difference. Thank you.
GINEBRA – Más de uno de cada cinco estadounidenses hospitalizados con COVID-19 también contrajo una infección bacteriana. Si no reciben antibióticos eficaces, quienes tuvieron la suerte de derrotar al coronavirus podrían caer a causa de uno de estos patógenos no tan novedosos.
Lamentablemente, el proceso de desarrollo de nuevos antibióticos se está debilitando. A menos de 100 años del desarrollo de la penicilina, las “superbacterias” resistentes a los medicamentos amenazan con ganar la delantera en nuestra lucha contra las infecciones bacterianas.
En todo el planeta, las superbacterias ya representan un coste enorme para los sistemas de atención de salud. Cerca de 700.000 personas mueren cada año en el mundo debido a la resistencia antimicrobiana (AMR, por sus siglas en inglés). Sin tratamientos nuevos y mejores, la cifra podría llegar a diez millones para 2050.
We hope you're enjoying Project Syndicate.
To continue reading, subscribe now.
Subscribe
orRegister for FREE to access two premium articles per month.
Register
Already have an account? Log in